CDKN2A and ovarian neoplasm: Beyond genomic and hormone receptor expression, p16 expression levels were assessed by immunohistochemistry (IHC) as it is clear from multiple studies including our own1–4 that cases with abnormal p16 expression (both loss and overexpression) defines its own molecular subtype of LGSOC and has been linked to shorter survival outcome in the large Ovarian Tumor Tissue Analysis consortium study16.